| Detected | Trial | Change |
|---|---|---|
| 2026-05-28 | NCT06492616 A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2… |
Trial sites expanded: 536 -> 541 locations |
| 2026-05-23 | NCT07287098 A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen… |
Trial sites expanded: 42 -> 60 locations |
| 2026-05-14 | NCT06979596 A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) |
Trial sites expanded: 52 -> 55 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib | Metastatic Breast Cancer | Active, Not Recruiting |
| Phase 3 | |||
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of… | Breast Cancer, Early Breast Cancer | Recruiting |
| NCT05512364 | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | ER-positive Breast Cancer | Recruiting |
| NCT06492616 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2… | Breast Cancer | Recruiting |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early… | Breast Cancer, Early Breast Cancer | Recruiting |
| NCT03011684 | Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial | Infertility | Recruiting |
| NCT05645536 | Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have… | Breast Cancer | Enrolling by Invitation |
| NCT04906395 | Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT05514054 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early… | Breast Neoplasms | Active, Not Recruiting |
| NCT06440967 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer… | Hot Flashes | Active, Not Recruiting |
| NCT05306340 | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With… | Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer | Active, Not Recruiting |
| NCT00310180 | Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have… | Breast Adenocarcinoma | Active, Not Recruiting |
| NCT01272037 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in… | Breast Ductal Carcinoma In Situ | Active, Not Recruiting |
| Phase 2 | |||
| NCT06348134 | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+… | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Recruiting |
| NCT06179303 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone… | Anatomic Stage III Breast Cancer AJCC v8 | Recruiting |
| NCT05982093 | Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | Breast Cancer | Recruiting |
| NCT06434064 | Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With… | Anatomic Stage III Breast Cancer AJCC v8 | Recruiting |
| NCT05501704 | ETHAN - ET for Male BC | Male Breast Cancer | Recruiting |
| NCT05941520 | Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal… | Breast Atypical Hyperplasia | Recruiting |
| NCT06184750 | Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women… | Breast Atypical Ductal Hyperplasia | Recruiting |
| NCT06979596 | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Malignant Neoplasm | Recruiting |
| NCT06195306 | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction | Breast Atypical Hyperplasia | Recruiting |
| NCT06075953 | DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active… | Ductal Carcinoma in Situ | Recruiting |
| NCT05035836 | A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients… | Breast Cancer | Recruiting |